◼ Archived
Business
CBER official overruled review team’s rejection of new Replimune melanoma drug
An official within the FDA's CBER overruled a review team's initial rejection of a new Replimune melanoma drug.
Replimune
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Replimune
This hub groups 3 separate news trends connected to Replimune, spanning July 31, 2026 through September 3, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 25 article observations and 22 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
FDA approves Replimune melanoma drug previously rejected twice
Replimune's melanoma drug wins FDA approval on third attempt, but stock price falls.
◼ Archived
Business
🔮 holds ✗
FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
An FDA advisory committee has voted 10-3 in favor of Replimune’s oncolytic immunotherapy for melanoma, marking a turning point for the twice-rejected treatment.